Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes (ACTH)

This study has been completed.
Information provided by:
Arizona Kidney Disease and Hypertension Center Identifier:
First received: November 25, 2009
Last updated: July 13, 2011
Last verified: July 2011
To determine if H.P. Acthar Gel (repository corticotrophin) has the same anti-proteinuric effects seen with the synthetic ACTH analogue in Europe.

Condition Intervention Phase
Nephrotic Syndromes
Drug: Repository corticotrophin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

Resource links provided by NLM:

Further study details as provided by Arizona Kidney Disease and Hypertension Center:

Primary Outcome Measures:
  • Acthar has the same anti-proteinuric effects in a wide range of glomerulonephropaties as seen with synthetic ACTH (Synacthen) in Europe [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Acthar has similar anti-lipid effects as seen with Synacthen. [ Time Frame: 6 months ]

Estimated Enrollment: 18
Study Start Date: December 2009
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Repository corticotrophin
    Acthar 80 IU SQ once a week and titrated up to twice a week
    Other Name: H.P. Acthar Gel
Detailed Description:
Synthetic ACTH (Synacthen Depot) has been used in the treatment of Nephrotic Syndrome in Europe. It has been proven effective in treating idiopathic membranous nephropathy and other various diagnoses involving the kidneys. However, Synacthen is not available in the United States. The only preparation available is the H.P. Acthar Gel (repository corticotrophin) which has been widely used in the treatment of infantile spasms and has been available longer than Synacthen. Therefore, we are conducting this study to determine if H.P. Acthar Gel (repository corticotrophin) is as effective in reducing protein in the urine as seen in synthetic ACTH in Europe.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Nephrotic Syndrome with a minimal of 3.5grams of protein per 24 hr period, measured via either 24hr urine collection or spot protein to creatinine ratio.
  • Males and post-menopausal, surgically sterile, or non-lactating and non-pregnant females using adequate contraception
  • Biopsy proven diagnosis of nephrotic syndrome due to Lupus glomerulonephritis, Membranous nephropathy, Focal segmental glomerulosclerosis, Minimal Change disease, Diabetic nephropathy (type 2)or IgA nephropathy.
  • Greater than 18 years of age
  • Willing and able to give informed consent
  • Diabetics are on insulin or willing to start insulin during the study

Exclusion Criteria:

  • Previous intolerance to native ACTH or proteins of porcine origin
  • History of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, primary adrenocortical insufficiency or adrenocortical hyperfunction.
  • Expected to begin renal replacement therapy or receive a transplant within the next year.
  • Recent cardiovascular event within 3 months of screening including: Myocardial Infarction, CVA, TIA, New York Heart Association Functional Class III or IV failure, Obstructive valvular heart disease, or hypertrophic cardiomyopathy, second or third degree atrioventricular block not successfully treated with a pacemaker.
  • History of HIV
  • Know peptic ulcer disease.
  • SBP> 160 or DBP > 100 at time of enrollment
  • New diagnosis of cancer or recurrent cancer within 2 years of screening
  • History of alcohol or drug abuse within 12 months of study entry.
  • Receipt of any investigational drug within 30 days of enrollment.
  • Anticipated major surgery during trial period
  • Psychiatric disorder that interferes with the patient's ability to comply with the protocol.
  • Inability to cooperate with study personnel or history of noncompliance to medical management
  • Active infection within 1 month of screening
  • Poorly controlled diabetes with an HbA1C > 10%
  • Type 1 diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01021540

United States, Arizona
Phoenix, Arizona, United States, 85032
Sponsors and Collaborators
Arizona Kidney Disease and Hypertension Center
Principal Investigator: Sungchun Lee, M.D. Arizona Kidney Disease and Hypertension Center
  More Information

Responsible Party: Sungchun Lee, MD, AKDHC Identifier: NCT01021540     History of Changes
Other Study ID Numbers: 2009003
Study First Received: November 25, 2009
Last Updated: July 13, 2011

Keywords provided by Arizona Kidney Disease and Hypertension Center:

Additional relevant MeSH terms:
Nephrotic Syndrome
Pathologic Processes
Kidney Diseases
Urologic Diseases
Adrenocorticotropic Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 27, 2017